Valuation : Allergy Therapeutics plc

Market Cap 301M 407M 350M 332M 564M 38.86B 567M 3.94B 1.52B 19.77B 1.53B 1.49B 62.47B P/E 2026 *
-5.22x
P/E 2027 * -
Enterprise Value 345M 467M 402M 381M 647M 44.57B 651M 4.52B 1.74B 22.68B 1.75B 1.71B 71.65B EV / Sales 2026 *
5.76x
EV / Sales 2027 * -
Free-Float
11.23%
Yield 2026 *
-
Yield 2027 * -
1 day+7.14%
3 months+15.38%
6 months+36.36%
Current year+36.36%
Current year 0.11
Extreme 0.11
0.15
1 year 0.09
Extreme 0.09
0.15
3 years 0.01
Extreme 0.01
0.15
5 years 0.01
Extreme 0.01
0.54
10 years 0
Extreme 0.0001
0.54
Manager TitleAgeSince
Chief Executive Officer 62 2009-06-30
Director of Finance/CFO - 2023-08-10
Corporate Officer/Principal - 2013-04-30
Director TitleAgeSince
Director/Board Member 62 2009-06-10
Chairman 75 2011-01-03
Director/Board Member 69 2017-06-05
Change 5-day change 1-year change 3-year change Capi.($)
+7.14%-.--% - - 407M
-1.48%-5.59%+39.55%-6.16% 78.04B
+5.38%-1.09%+512.38%+36.80% 57.48B
-1.42%-4.24%-19.59%-38.20% 57.4B
-0.56%-2.21%-11.34%+27.29% 48.81B
+1.93%-2.37%-0.87%+149.45% 45.5B
+0.80%-1.67%+49.90%-15.98% 32.08B
-1.47%-4.17%+46.17%+89.12% 24.62B
-0.85%-8.64%-4.39%+161.31% 20.77B
-0.09%-3.61%+62.49%+98.37% 15.75B
Average +0.94%-3.87%+74.92%+55.78% 42.27B
Weighted average by Cap. +0.38%-3.71%+90.55%+37.21%

Financials

2026 *2027 *
Net sales 59.9M 81.01M 69.79M 66.09M 112M 7.74B 113M 785M 302M 3.94B 304M 298M 12.44B -
Net income -55.7M -75.33M -64.9M -61.45M -104M -7.2B -105M -730M -281M -3.66B -283M -277M -11.57B -
Net Debt 44.2M 59.77M 51.5M 48.76M 82.92M 5.71B 83.34M 579M 223M 2.91B 224M 220M 9.18B -
Logo Allergy Therapeutics plc
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Employees
584
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0475GBP
Average target price
0.1300GBP
Spread / Average Target
+173.68%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!